sikakoira kirjoitti: Ma Elo 31, 2020 11:32 pm
https://www.is.fi/ulkomaat/art-2000006619603.html
Afrikassa on todettu hämmentävän vähän koronakuolemia – asiantuntijat pelkäävät hiljaista epidemiaa
Tottakai asiantuntijat pelkäävät pahinta mutta looginen selitys tapauksien vähyyteen on malarialääkitys joka on hyvin kattava.
Nopeasti ajateltuna, tuo voisi olla looginen selitys, mutta Afrikassa on tehty paljon myös asioita oikein; “The treatment itself does seem to be working, because people when they are put on treatment they do not develop much symptoms," he said. "Although I said earlier we do not work with observation, the indicators are talking. Very low mortality and very low number of symptomatic [cases].”
Another reason for Djibouti’s apparent success, Zoutien said, is that the government has “a very, very aggressive testing strategy” and an even more aggressive approach to contact tracing. Before patients can leave the hospital, they need to test negative two times within 48 hours.
Offering one explanation, he said “chloroquine anti-malarial drugs act positively on the virus.”
“That’s what we think, though nothing has confirmed it,” he said.
https://www.voanews.com/covid-19-pandem ... ge-caution
Lisäksi (hydroksi)klorokiinin HCQ ja HCQ+ atsitromysiini AZTH-yhdistelmälääkityksen tehosta (l. tehonpuutteesta) ja haittavaikutuksista löytyy myös paljon tutkittua tietoa. COVID 19 hoidetaan HCQ:lla huomattavasti suuremmilla annoksilla kuin malarialääkityksessä, joka johtaa hyvin suurella todennäköisyydellä sydänongelmiin, esim. vaarallisiin rytmihäiriöihin.
Alla tuoreita tutkimustuloksia, jos kiinnostaa tutustua:
https://www.sciencedaily.com/releases/2 ... 135245.htm
https://globalheartjournal.com/articles ... 18.11.002/
Alla Barcelonassa tehty RCT, joka osoitti hoitotehon puutteen:
A second large PEP trial has come up empty as well, its leader tells Science. Carried out in Barcelona, Spain, that study randomized more than 2300 people exposed to the virus to either hydroxychloroquine or the usual care. There was no significant difference between the number of people in each group who developed COVID-19, says Oriol Mitjà of the Germans Trias i Pujol University Hospital. Mitjà says he has submitted the results for publication.
https://clinicaltrials.gov/ct2/show/NCT04304053
In this trial, high doses of hydroxychloroquine did not prevent illness compatible with Covid-19 when initiated within 4 days after a high-risk or moderate-risk exposure.
https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
Evidence on the benefits and harms of using hydroxychloroquine or chloroquine to treat COVID-19 is very weak and conflicting.
https://www.acpjournals.org/doi/10.7326/M20-2496
Tässä osoitetaan, että HCQ ei pysty estämään SARS-cov-2-viruksen pääsyä ihmisen keuhkosoluun.
Hydroxychloroquine (HCQ) has been given to thousands of individuals worldwide but definitive evidence for HCQ efficacy in treatment of COVID-19 is still missing.
We evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (VeroE6) but not in a model of reconstituted human airway epithelium.
Neither HCQ nor HCQ+AZTH showed a significant effect on the viral load levels in any of the tested compartments. When the drug was used as a pre-exposure prophylaxis (PrEP), HCQ did not confer protection against acquisition of infection. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral treatment for COVID-19 in humans.
https://www.nature.com/articles/s41586-020-2558-4